The low-sensitivity (25% true-positives) and low-specificity (14.5% true-negatives) of the PSA-blood-test led to the recommendation against this test as a routine screening-test (6), highlighting the need for a more accurate screening-test for prostate cancer. This evidence concerns the gene KLK3 and prostate cancer.